Nonetheless, phase I/II clinical trials are currently evaluating the safety and efficacy of 2nd-generation EpCAM CAR-T cell therapy in several cancers, including PCa (NCT03013712). The gene discussed is EPCAM; the disease is posterior cortical atrophy.